AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being ...

AbbVie's acquisition of Allergan significantly increased the firm's debt level. We expect the firm's net debt position to peak at close to $70 billion in 2020 but given the strong cash flows of AbbVie ...

He emphasized the consistent outperformance of the ex-Humira platform, which grew over 18% annually and accelerated to 22% growth in Q4. The company projects mid-single-digit revenue growth in 2025, ...

In response to growing demand for personalized, patient-centric aesthetic solutions1,2, Allergan Aesthetics, an AbbVie Company, is proud to unveil the new AA Signature program, an innovative approach ...

Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive ...

Dover noted that some people find it “creepy” for AI to determine their ideal look, especially when it comes to aesthetic choices. “In current practice, they’re relying on the doctor or ...

Still, the BMO note stated that while Wednesday’s label expansion might only be an “incremental upside” to Lilly’s shares, it points to the pharma’s “progress … in expanding its footprint in ...

"No aesthetic reason could justify the use of a carcinogen in our food supply." Red 3 is banned for food use in Europe, Australia, and New Zealand except in certain kinds of cherries. The dye will ...